15 results
10-K
2023 FY
NMRA
Neumora Therapeutics, Inc. Common Stock
7 Mar 24
Annual report
4:05pm
indication as the original innovative drug or for another indication, where the applicant does not own or have a legal right of reference to all … a Center for Medicare and Medicaid Innovation at the CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending
8-K
EX-99.1
NMRA
Neumora Therapeutics, Inc. Common Stock
8 Jan 24
Regulation FD Disclosure
8:32am
Data on File.. PTE = patent term extension. 16
2024 and 2025 Are Catalyst Rich Years for Neumora Built at Scale Leading Pipeline Innovative Approach
424B4
NMRA
Neumora Therapeutics, Inc. Common Stock
18 Sep 23
Prospectus supplement with pricing info
4:12pm
treatment for MDD. Dr. Nick Brandon, our Chief Scientific Officer, previously served as Chief Scientist of AstraZeneca’s Neuroscience Innovative Medicines … success is highly dependent on our ability to discover, develop and obtain marketing approval for new and innovative products on a cost-effective basis
S-1/A
u90fkpw
11 Sep 23
IPO registration (amended)
6:07am
S-1
om9iilyomh5q8 9rwz8y
25 Aug 23
IPO registration
5:03pm
DRS/A
9juf camgwiin9ln9a
9 Aug 23
Draft registration statement (amended)
12:00am
DRS/A
hiq sghpt14
30 Jun 23
Draft registration statement (amended)
12:00am
DRS/A
hvsuu
2 May 23
Draft registration statement (amended)
12:00am
DRS/A
ev59oyf
2 Sep 22
Draft registration statement (amended)
12:00am
DRS/A
35kxorar
10 Jun 22
Draft registration statement (amended)
12:00am
DRS/A
jocvin
2 May 22
Draft registration statement (amended)
12:00am
DRS/A
wrw8k no3
23 Dec 21
Draft registration statement (amended)
12:00am
DRS
jixixzy
8 Nov 21
Draft registration statement
12:00am
- Prev
- 1
- Next